Latest Regulatory News

Althea Group Holdings reported a resilient September quarter with $5.4 million in receipts despite a major strike in British Columbia, bolstered by a $2.53 million capital raise and expansion in the US THC beverage market.

Patrys Limited has raised $1.77 million through a fully underwritten entitlement offer to fund preclinical studies and business development for its deoxymab therapeutic antibodies. The company also completed a capital consolidation and held a successful AGM, signaling a strategic pivot into immunology and inflammation.

Southern Palladium has cleared major regulatory hurdles and confirmed robust economics for its Bengwenyama platinum group metals project, supported by a $20 million capital raise to fund next-stage development.

Reach Resources has made significant progress at its Murchison South Gold Project, confirming high gold recovery rates and preparing for an extensive drilling campaign to upgrade resource confidence.

Firebrick Pharma is set to expand its Nasodine product line with the launch of a new throat spray, targeting export markets starting November 2025, beginning with Singapore.

Anax Metals has made significant progress on its Whim Creek Copper-Zinc project, securing a waste rock processing agreement and continuing efforts to finalize project financing.

Magnetite Mines has made significant strides in developing its Razorback Iron Ore Project, securing $3.86 million in new funding and uncovering promising rare earth mineralisation at Ironback Hill. The company continues to navigate strategic partnerships and regulatory approvals to advance its long-life magnetite project.

CONNEQT Health reports robust 50% quarter-on-quarter growth in Pulse device sales and launches a new pricing strategy to boost recurring revenue. The company also secures a significant US clinical trial contract and advances cost-cutting efforts.

D3 Energy has secured formal acceptance of its Production Right Application for the ER315 permit in South Africa, marking a pivotal step toward production. The company also broadened its portfolio with new helium and hydrogen permits in Australia and began trading on the US OTCQX market.

Cleo Diagnostics has successfully completed Stage 1 of the Medical Device Single Audit Program, marking a significant step toward FDA submission and global commercialisation of its ovarian cancer test.

Horizon Oil’s recent acquisition of Thai gas assets and a decade-long permit extension at Maari have propelled production and reserves, underpinning a strong financial quarter and sustained shareholder returns.

OncoSil Medical reports a remarkable 917% increase in quarterly cash receipts alongside promising clinical trial results and key European market entries, signaling robust momentum in its pancreatic cancer treatment rollout.